| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 23, 2018Virtual Press Office and PR Newswire: General Trade show news
When adolescents and adults with type 1 diabetes (T1D) used a new continuous glucose monitoring (CGM) device containing a sensor that can remain implanted in the arm for up to 180 days, the system...
-
Jun 23, 2018Virtual Press Office and PR Newswire: General Trade show news
A dual-hormone, artificial pancreas1 delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an...
-
Jun 23, 2018Virtual Press Office and PR Newswire: General Trade show news
Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the Horizon™ Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted...
-
Jun 23, 2018Virtual Press Office and PR Newswire: General Trade show news
Findings from CONFIRM – a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL versus insulin glargine...
-
Jun 23, 2018Virtual Press Office and PR Newswire: General Trade show news
Ozempic® (semaglutide) injection 0.5 mg or 1 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass...
